Navigation Links
Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
Date:9/6/2010

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood, according to a report published online today that will appear in the January 2011 print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

"In recent years, there has been a growing awareness that the psychological, spiritual and existential crises often encountered by patients with cancer and their families need to be addressed more vigorously," the authors write as background information in the article. "From the late 1950s to the early 1970s, research was carried out exploring the use of hallucinogens to treat the existential anxiety, despair and isolation often associated with advanced-stage cancer. Those studies described critically ill individuals undergoing psychospiritual epiphanies, often with powerful and sustained improvement in mood and anxiety as well as diminished need for narcotic pain medication."

Despite initial promising results, no follow-up research had been conducted; however, the medical value of hallucinogens is now being re-examined in psychiatric settings, the authors note. Charles S. Grob, M.D., of Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, explored the safety and efficacy of psilocybina hallucinogen with some psychological effects similar to lysergic acid diethylamide (LSD)among 12 adults with advanced-stage cancer and anxiety.

Participants served as their own controls; in two six-hour treatment sessions several weeks apart, they were given clear capsules either of active psilocybin (in a dose of 0.2 milligrams per kilogram) or a placebo (niacin, 250 milligrams) in random order. Physiological responses such as blood pressure, heart rate and temperature were measured before and after, and psychological measures including assessments of depression, mood and anxiety we
'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Panel Appears Skeptical Over Key Avandia Data
2. Plasma protein appears to be associated with development and severity of Alzheimers disease
3. Celebrex Appears Easier on Stomach for Arthritis Patients
4. NAMI Medical Director Honored with APA Patient Advocacy Award; Appears in CNN Health and Huffington Post Columns
5. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
6. Hospitalization Appears to Help Personality Disorder Patients
7. How health care is paid for appears to impact outcome
8. Protein Appears Key to Intestinal Balance
9. Eggs Being Produced by Recall Farms Safe, if Pasteurized, Experts Say
10. Drug-eluting stents confirmed safe, effective for long-term use
11. Declare Your Skin-dependence this Holiday with Patriotic, Playful Products from TruKid, the Award-Winning Line of Safe, Natural Products for Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... finds chlorthalidone most likely to prevent heart failure, ... Tried-and-true diuretics maintain their status as the best ... high blood pressure, new research concludes. , The ... a calcium channel blocker, an ACE inhibitor and ...
... Nov. 18 The U.S. Agency for International Development (USAID) ... up with Chicago Cubs Charities Nov. 17 to donate $100,000 ... Basic School and Education Center for Integrated Health (CESI). , ... and...Loyola and Creighton (universities) to help children and their families ...
... Release Statewide Data , HARRISBURG, Pa., Nov. 18 Pennsylvania is ... and adults living with autism, according to the Pennsylvania Autism Census ... , "With the release of this report, Pennsylvania becomes the first ... to meet the needs of the rapidly growing population of children ...
... The National Patient Safety Foundation (NPSF) today issued the following position ... The National Patient Safety Foundation recognizes vaccine-preventable, ... and supports mandatory, influenza vaccination of ... patients, health care workers, and the community. NPSF appreciates, ...
... Nov. 18 Hospice workers have seen patients hang onto ... from the Frances Payne Bolton School of Nursing and the ... will study what drives the dying to resolve unfinished business. ... Prince-Paul from nursing and Julie Exline from arts and sciences ...
... at Mount Sinai School of Medicine set out to ... years: How do dietary restrictionand the reverse, overconsumptionproduce protective ... in a two-part study led by Charles Mobbs, PhD, ... at Mount Sinai School of Medicine, published in the ...
Cached Medicine News:Health News:Diuretics Still Best Treatment for High Blood Pressure 2Health News:USAID, Cubs Charities Make a Grand Slam for Health and Basic Education 2Health News:PA Governor Rendell: New Report Shows Demand for Autism Services will Continue to Rise 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 2Health News:National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 3Health News:Research Collaboration Focuses on Unfinished Business at the End of Life 2Health News:Scientists find molecular trigger that helps prevent aging and disease 2Health News:Scientists find molecular trigger that helps prevent aging and disease 3
(Date:9/2/2014)... -- Actavis plc (NYSE: ACT ) today ... has accepted for filing Actavis, New Drug Application (NDA) ... diarrhea and abdominal pain in men and women with ... eluxadoline has been granted priority review status by the ... "The NDA filing of eluxadoline marks an important ...
(Date:9/2/2014)... CITY, Calif. , Sept. 2, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Wednesday, September 10, 2014 at 10:20 a.m. ET. The ... York in New York City . ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014   Mast Therapeutics, ... Executive Officer, Brian M. Culley , will present at the ... Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the ... New York . Interested parties can ... Therapeutics web site at www.masttherapeutics.com . An archived presentation will ...
Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3
... , WASHINGTON, Dec. 14 ... counsel on global and domestic communications and issues management, ... PositiveID Corporation (Nasdaq: PSID ) to serve as ... will conduct media relations for PositiveID,s corporate communications and ...
... , NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ ... today announced that it had received a complete response ... related to its New Drug Application ("NDA") for Onrigin(TM) ... indicates that the FDA cannot approve the Company,s NDA ...
Cached Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: